Microarrays Market Size, Share & Industry Analysis, By Offering (Products {Instruments and Consumables} and Software & Services), By Type (DNA Microarray, Protein Microarray, Tissue Microarray, and Others) By Application (Drug Discovery & Development, Diagnostics, Research, and Others), By End User (Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Diagnostic Laboratories, and Others), and Regional Forecast, 2025-2032

The global microarrays market size was valued at USD 6.49 billion in 2024. The market is projected to grow from USD 6.85 billion in 2025 to USD 10.85 billion by 2032, exhibiting a CAGR of 6.78% during the forecast period. North America dominated the microarrays market with a market share of 43.3% in 2024.

Microarrays are lab tools that use hybridization to analyze thousands of genes or proteins simultaneously from a sample. They consist of a solid surface, such as a glass slide, that holds a grid of tiny spots called probes, which are short pieces of DNA or other molecules. Prominent factors such as rising demand for these tools due to increasing research in genomics, need for innovative therapies, and technological advancements fueled the adoption of microarray technologies.

Furthermore, the market encompasses several major players with Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., and others. Broad portfolio with innovative product launch, and strong geographic presence expansion have supported the dominance of these companies in the global market.

MARKET DYNAMICS

MARKET DRIVERS

Rising Incidence of Chronic and Infectious Diseases to Propel Market Growth

The increasing global burden of chronic and infectious diseases necessitates enhanced genetic and molecular profiling tools for earlier diagnosis, targeted treatment, and personalized healthcare. These advanced tools enable accurate identification of pathogens and genetic predispositions to chronic conditions, allowing for faster interventions, tracking disease outbreaks, assessing antimicrobial resistance, and stratifying individuals for personalized prevention and treatment strategies. Microarrays, especially gene-expression panels, methylation arrays and protein arrays, provide a high throughput route for biomarker discovery and clinically validated tests, which directly accelerates their adoption in research and selected clinical workflows.

• For instance, according to the National Cancer Institute, around 2,041,910 new cases of cancer are estimated to be diagnosed in 2025 in the U.S.

MARKET RESTRAINTS

Increasing Adoption of Alternative Advanced Technologies to Restrict Market Expansion

The adoption of advanced technologies alongside or instead of traditional microarrays is increasing, driven by their enhanced capabilities in next-generation sequencing (NGS) and electronic detection systems. While microarrays have been crucial for applications including gene expression and genotyping, the use of NGS offers superior sensitivity, the ability to detect novel transcripts and mutations, and a more comprehensive understanding of the transcriptome and genome. This makes it the preferred tool for applications such as non-invasive prenatal testing and precision medicine. This results in a slower growth of the overall microarrays market.

• For example, according to an article published by Cytiva in April 2019, NGS is gradually replacing microarrays, especially in areas such as non-invasive prenatal testing (NIPT), due to its higher resolution and ability to detect novel genetic variants that microarrays cannot.

MARKET OPPORTUNITIES

Increasing Focus on Personalized Medicine to Create Lucrative Growth Opportunities

Personalized medicine is accelerating demand for high-throughput, reproducible molecular profiling, and microarrays offer cost-effective panels ideal for large cohorts. By enabling rapid patient stratification and robust biomarker validation, these tools shorten time-to-market for targeted therapies and companion diagnostics. Additionally, when combined with AI-driven analytics and cloud reporting, array data become actionable clinical insights that drive service revenue, and expansion into protein and methylation arrays lets vendors address broader multi-omics needs in precision oncology and complex disease. Together, these trends expand the overall market across diagnostics, pharma, and clinical labs.

MICROARRAYS MARKET TRENDS

Increasing Usage of Protein and Specialized Microarrays is a One of Significant Market Trend

In recent years, the marketspace is witnessing the increasing usage of protein and specialized microarrays. This is due to their high-throughput capability for studying thousands of proteins simultaneously, enabling advancements in disease diagnosis, drug discovery, and understanding complex biological processes. Specialized advancements such as cell-free protein expression and improved surface chemistries are enhancing protein detection, function analysis, and biomarker discovery for cancers and autoimmune diseases. The future growth relies on technical improvements in sensitivity and specificity, novel array types such as cell-free microarrays, and the development of robust bioinformatics to support these powerful tools.

MARKET CHALLENGES

High Cost of Instrumentation & Maintenance to Hamper Market Growth

Microarray systems require sophisticated instruments such as microarray scanners which require high upfront investment. High-end instruments, automated TMA devices, and even manual kits for tissue microarray construction are costly, in turn creating a financial burden. Additionally, the need for skilled personnel and bioinformatics capability to handle and interpret large, complex data sets produced by microarray experiments also requires high capital investment. All these factors are anticipated to limit the microarrays market growth to certain extent.

• For instance, according to Arrayit Corporation, the cost of SpotLight Turbo Microarray Scanner is around USD 73,510.

Request a Free sample to learn more about this report.

Segmentation Analysis

By Offering

High Demand for Integrated Software Contributed to Growth of Segment

On the basis of the offering, the market is classified into products and software & services.

To know how our report can help streamline your business, Speak to Analyst

The products segment accounted for the leading microarrays market share in 2024. The growing demand for products by research institutions, pharmaceutical & biotechnology labs, coupled with increasing adoption in diagnostics have primarily driven the segment growth. Additionally, advancements in genomics, rising incidence of chronic diseases requiring precise diagnostic tools, and the increasing application of microarrays in drug development, cancer research, and pharmacogenomics also boost the segment growth. Moreover, new product launches by key players also drive the growth.

• For instance, in August 2023, Thermo Fisher Scientific Inc. launched a new chromosomal microarray which was designed to improve the productivity of cytogenetic research labs.

By Type

High Usage of DNA Microarrays Contributed to Segmental Growth

On the basis of type, the market is classified into DNA microarray, protein microarray, tissue microarray, and others.

The DNA microarrays segment accounted for the dominating share of the market in 2024. The widespread applications of DNA microarrays in genotyping/expression studies used in research, diagnostics and pharmaceutical drug development play a crucial role in the dominance of the segment. Additionally, advantages of these tools such as cost-effectiveness, high gene monitoring capacity, and controlled specificity for single nucleotide polymorphism (SNP) analysis further propels the growth of the segment. Moreover, presence of well-established companies in offering these products also supplements the segment growth.

• For instance, Illumina Inc. is one of the major players in the market that offer DNA microarrays for various applications. 

The protein microarrays segment is expected to grow at a CAGR of 12.68% over the study period. 

By Application

Increasing Focus on Genomics Research Fuels Growth of Research Applications Segment

In terms of application, the market is categorized into drug discovery & development, diagnostics, research, and others.

The research segment captured the largest microarrays market share in 2024. In 2025, the segment is anticipated to dominate with 46.1% share. Microarrays play an important role in research applications by enabling the simultaneous analysis of vast amounts of DNA or RNA sequences, providing a powerful tool for gene expression profiling, comparative genomics, disease diagnosis, and drug discovery. These products allow researchers to study the function of genes under different conditions, identify genetic variations, characterize complex diseases including cancer, and assess how patients respond to treatments.

• For instance, a study was published in the Pathology and Laboratory Medicine International in November 2023, which demonstrated the applications of DNA microarray techniques in diagnosing infectious diseases.

The diagnostic segment is expected to witness 8.96% growth over the forecast period.  

By End User

Early Adoption by Research & Academic Institutes Propelled Segment Growth

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, research & academic institutes, diagnostic laboratories, and others.

In terms of end user, in 2024, research & academic institutes held the dominating share of the global market. This owing to their early adoption, increasing government support for research and development activities, large installed base, and rising number of partnerships with other entities for innovative applications. Furthermore, the segment is set to hold 45.7% share in 2025.

• For instance, the Bill & Melinda Gates Foundation provided funding for the research conducted by the Medical Research Council (MRC) Unit, The Gambia, at the London School of Hygiene & Tropical Medicine (LSHTM). The research was focused on the study of the use of microarray patches to vaccinate children.

In addition, the diagnostic laboratories segment is projected to grow at a CAGR of 8.70% during the forecast period.

Microarrays Market Regional Outlook

By geography, the market is divided into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

NORTH AMERICA

To get more information on the regional analysis of this market, Request a Free sample

North America captured the dominating share of the global market in 2023 valuing at USD 2.67 billion and also took the leading share in 2024 with USD 2.81 billion. The dominance of the region can be attributed to the factors such high R&D spending in biotechnology & pharmaceutical industry, strong genomics & proteomics research, and established healthcare & diagnostics infrastructure. In 2025, the U.S. market is estimated to reach USD 2.03 billion.  The country is home to leading market players and a high burden of chronic & genetic disorders which supports the country’s market growth.

• For instance, in January 2025, Vaxxas received the funding of USD 2 million from the United States Biomedical Advanced Research and Development Authority (BARDA) for advanced microarray patches for vaccination.

EUROPE

During the forecast period, the European region is anticipated to grow at a CAGR of 6.53%, which is the second largest region among all the regions and touch the valuation of USD 1.57 billion in 2025. Key factors responsible for this include increasing investments in biotechnology & genomics research, advanced healthcare infrastructures, along with rising focus on precision medicine. Backed by these factors, countries including the U.K. anticipate to record the valuation of USD 0.33 billion, Germany to record USD 0.38 billion, and France to record USD 0.30 billion in 2025.

ASIA PACIFIC

After Europe, the market in Asia Pacific is valued to reach USD 1.54 billion in 2025 and secure the position of third-largest region in the market. In the region, India and China both are estimated to reach USD 0.22 billion and USD 0.42 billion respectively in 2025.

LATIN AMERICA and MIDDLE EAST & AFRICA

Furthermore, Latin America and Middle East & Africa regions are likely to witness a slower growth over the study period. The Latin America market in 2025 is set to record USD 0.40 billion as its valuation. Improvements in digital infrastructure are anticipated to drive the adoption of these products in these regions in the coming years. In Middle East & Africa, GCC is set to attain the value of USD 0.15 billion in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Availability of Broad Product Portfolio coupled with Strong Geographical Presence of Leading Companies Supported their Dominating Position

The global microarrays market is fragmented in structure with a small number of large life-science companies and a growing number of mid-sized specialists and startups focused on protein arrays, tissue arrays, or advanced services. Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc. are some of the leading companies in the market. These companies have broad product portfolios, global commercial footprints, and high penetration among end users, which supports their market dominance.

The other prominent players include Arrayit Corporation, Creative Biolabs, CD Genomics, and others. These companies are focusing specifically on innovative product and service offerings to gain a competitive edge in the market.

• For instance, in August 2024, CD Genomics announced the availability of microarray data analysis methods at their bioinformatics-analysis division.

LIST OF KEY MICROARRAY COMPANIES PROFILED

• Agilent Technologies Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio Rad Laboratories Inc. (U.S.)
• Illumina Inc. (U.S.)
• Arrayit Corporation (U.S.)
• CDI Labs (Puerto Rico)
• Creative Biolabs (U.S.)
• Creative Proteomics (U.S.)
• Merck KGaA (Germany)
• CD Genomics (U.S.)

KEY INDUSTRY DEVELOPMENTS

• March 2025: UNSW Sydney announce their first Applied Biosystems Axiom PangenomiX Array project for genotyping hundreds of thousands of genetic variants.
• December 2023: Spectrum Solutions acquired Alimetrix, Inc., and Microarrays, Inc., for expansion of its lab capabilities and testing capabilities.
• October 2023: Sengenics Corporation LLC introduced the i-ome discovery platform, a comprehensive protein mhicroarray platform analyzing over 1,800 autoantigens.
• July 2023: Arrayjet collaborated with Chemspace to accelerate the Company’s small molecule microarray (SMM) service offering
• May 2020: PEPperPRINT GmbH announced the availability of PEPperCHIP Pan-Corona Spike Protein Microarray to support the coronavirus research.

REPORT COVERAGE

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation